Mexico's Director of the National Council of Science and Technology (Conacyt) has announced the development of a Mexican-made COVID-19 vaccine, 'Patria', CNN news website revealed on Wednesday.
According to Conacyt, the development of the Patria vaccine has already successfully passed preclinical studies in animals and will begin a Phase I trial in humans in April this year with about 90 to 100 volunteers.
Conacyt director Maria Elena Alvarez-Buylla said that the vaccine was being developed as part of a mixed investment strategy and collaboration between the Government of Mexico and the Mexican laboratory Avimex, which develops biological and pharmaceutical products for animal health. She also stated that the dose is based on a recombinant Newcastle virus.
Mexico's health regulator, Cofepris anticipates human trial results by May and if successful, the Patria vaccine could be approved by the end of 2021.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV